Drug Interactions between Copper and vadadustat

MONITOR: Smoking and alcohol consumption during therapy with vadadustat may increase the risk of gastrointestinal erosions. Serious erosions, including gastrointestinal bleeding and the need for red blood cell transfusions, have been reported during vadadustat clinical trials. Patients with a history of gastrointestinal erosion, peptic ulcer disease, and current tobacco smokers and alcohol drinkers may be at higher risk of gastrointestinal injury.

MANAGEMENT: Caution is advised if vadadustat is prescribed to current tobacco smokers or alcohol drinkers. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, hematemesis, trouble swallowing, chest or throat pain, and/or black, tarry stools.

Vadadustat is contraindicated in patients with uncontrolled hypertension as cases of hypertensive crisis including hypertensive encephalopathy and seizures have been reported. Patients with history of seizure disorders receiving this drug should be monitored closely and should contact their health care provider for premonitory symptoms or change in seizure frequency.

Vadadustat is contraindicated in patients with uncontrolled hypertension as cases of hypertensive crisis including hypertensive encephalopathy and seizures have been reported. Patients with history of seizure disorders receiving this drug should be monitored closely and should contact their health care provider for premonitory symptoms or change in seizure frequency.

Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.

The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

Vadadustat increases the risk of arterial and venous thrombotic events, including major adverse cardiovascular events. Patients with cardiovascular or cerebrovascular disease are at increased risk. Avoid the use of this drug in patients with history of myocardial infarction, cerebrovascular events, or acute coronary syndrome within the 3 months prior to starting treatment.

Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.

Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.

The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.

Vadadustat may cause hepatotoxicity. Liver enzymes and bilirubin should be measured prior to treatment initiation and monitored during treatment. This drug is not recommended in patients with cirrhosis, or active, acute liver disease.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements. GI absorption may be decreased in patients with malabsorption syndromes. Therefore, larger dosages may be required when these supplements are given orally. Parenteral administration may be appropriate.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.